Zobrazeno 1 - 10
of 85
pro vyhledávání: '"Rachel Hodge"'
Autor:
Owen D. Mitchell, Katie Gilliam, Daniela del Gaudio, Kelsey E. McNeely, Shaili Smith, Maria Acevedo, Meghana Gaduraju, Rachel Hodge, Aubrianna S.S. Ramsland, Jeremy Segal, Soma Das, Darren S. Bryan, Sanjukta Tawde, Shelly Galasinski, Peng Wang, Melissa Y. Tjota, Aliya N. Husain, Samuel Armato, Jessica Donington, Mark K. Ferguson, Kiran Turaga, Jane E. Churpek, Hedy L. Kindler, Michael W. Drazer
Structured AbstractImportancePatients with mesothelioma often have next generation sequencing (NGS) of their tumor. Tumor-only NGS may incidentally identify germline pathogenic or likely pathogenic (P/LP) variants despite not being designed for this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::98d1f80326066df9e90aa89a7e2548c1
https://doi.org/10.1101/2022.12.06.22282680
https://doi.org/10.1101/2022.12.06.22282680
Autor:
Diana Merino Vega, Katherine K. Nishimura, Névine Zariffa, Jeffrey C. Thompson, Antje Hoering, Vanessa Cilento, Adam Rosenthal, Valsamo Anagnostou, Jonathan Baden, Julia A. Beaver, Aadel A. Chaudhuri, Darya Chudova, Alexander D. Fine, Joseph Fiore, Rachel Hodge, Darren Hodgson, Nathan Hunkapiller, Daniel M. Klass, Julie Kobie, Carol Peña, Gene Pennello, Neil Peterman, Reena Philip, Katie J. Quinn, David Raben, Gary L. Rosner, Mark Sausen, Ayse Tezcan, Qi Xia, Jing Yi, Amanda G. Young, Mark D. Stewart, Erica L. Carpenter, Charu Aggarwal, Jeff Allen
Publikováno v:
JCO precision oncology. 6
PURPOSE As immune checkpoint inhibitors (ICI) become increasingly used in frontline settings, identifying early indicators of response is needed. Recent studies suggest a role for circulating tumor DNA (ctDNA) in monitoring response to ICI, but uncer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::adbae2458d94d624507bbcd92f730bce
https://pubmed.ncbi.nlm.nih.gov/35952319
https://pubmed.ncbi.nlm.nih.gov/35952319
Autor:
Konstantin Laktionov, Yi-Long Wu, Shun Lu, Kye-Young Lee, Thomas John, Terufumi Kato, Masahiro Tsuboi, Chong-Jen Yu, Jonathan W. Goldman, Manuel Domine, Yuri Rukazenkov, C. Grohe, Lingmin Zeng, Laura Bonanno, Jie He, Huu-Vinh Vu, Sang-We Kim, Frances A. Shepherd, Filippo de Marinis, Margarita Majem, Ajlan Atasoy, Rachel Hodge, Roy S. Herbst, Charuwan Akewanlop
Publikováno v:
New England Journal of Medicine. 383:1711-1723
BACKGROUND: Osimertinib is standard-of-care therapy for previously untreated epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC). The efficacy and safety of osimertinib as adjuvant therapy are unknown
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96a37d4ddf3885cfacbcfd109270c823
https://doi.org/10.1056/nejmoa2027071
https://doi.org/10.1056/nejmoa2027071
Autor:
Laura Bonanno, Jonathan W. Goldman, Chong-Jen Yu, Sang-We Kim, Christian Grohé, Ajlan Atasoy, Filippo de Marinis, Thomas John, Yuri Rukazenkov, Shun Lu, Terufumi Kato, Manuel Domine, Kye Young Lee, Margarita Majem, Huu-Vinh Vu, Charuwan Akewanlop, Rachel Hodge, Frances A. Shepherd, Roy S. Herbst, Masahiro Tsuboi, Lingmin Zeng, Yi-Long Wu, Konstantin Laktionov
Publikováno v:
Future Oncology
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Here, we summarize the initial results from the ADAURA clinical study looking at treatment with osimertinib in patients with a specific type of non-small cell lung cancer (also called NSCLC). Osimertinib (TAGRISSO®) is a medication used to treat a t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2fc84416d56be2d35e49b5abf6cc022
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=5211
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=5211
Autor:
Shun Lu, Suresh S. Ramalingam, Mustafa Ozguroglu, Ignacio Casarini, Manuel Cobo, M. Saggese, Terufumi Kato, Toon van der Gronde, Rachel Hodge
Publikováno v:
Clinical lung cancer. 22(4)
The LAURA trial (NCT03521154) will evaluate the efficacy and safety of osimertinib as maintenance therapy in patients with locally advanced, unresectable, epidermal growth factor receptor mutation-positive (EGFRm), stage III non-small-cell lung cance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92950ee4144695e354401ed0ee6e8b44
https://pubmed.ncbi.nlm.nih.gov/33558193
https://pubmed.ncbi.nlm.nih.gov/33558193
Autor:
MJ Boyer, S Bohnet, Jhanelle E. Gray, Ryan J. Hartmaier, S.S. Ramalingam, H Bischoff, C. Zhou, Astrid McKeown, Krishna C. Bulusu, Isamu Okamoto, Juliann Chmielecki, Byoung Chul Cho, Ying Cheng, F Imamura, J.C. Barrett, Margarita Majem, Rachel Hodge, Oliver Gautschi, M. Saggese, Meng-Chih Lin
Publikováno v:
61. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V..
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1e7b17ada9db9e1b200d6582673bbc97
https://doi.org/10.1055/s-0039-3403366
https://doi.org/10.1055/s-0039-3403366
Autor:
Yuri Rukazenkov, C Meyer zu Büschenfelde, S Bohnet, Niels Reinmuth, H Bischoff, Rachel Hodge, S.S. Ramalingam, A Rückert
Publikováno v:
61. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V..
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::312fcf3128d1ebf0d33fff67d3f57274
https://doi.org/10.1055/s-0039-3403353
https://doi.org/10.1055/s-0039-3403353
Autor:
Fumio Imamura, Suresh S. Ramalingam, Hirohiko Uchida, Kazuhiko Nakagawa, Andrew Walding, Yuichiro Ohe, Naoyuki Nogami, Sarah L. Vowler, Rachel Hodge, Takayasu Kurata, Isamu Okamoto, Shunichi Sugawara, Terufumi Kato
Publikováno v:
Japanese Journal of Clinical Oncology
In the FLAURA trial Japanese subset, osimertinib significantly improved median PFS versus standard-of-care (gefitinib) in patients with previously untreated EGFR (exon 19 deletion or L858R) mutation-positive advanced or metastatic NSCLC.
Backgro
Backgro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7170552ae331f96ee6df534d92993632
https://doi.org/10.1093/jjco/hyy179
https://doi.org/10.1093/jjco/hyy179
Autor:
Caicun Zhou, Suresh S. Ramalingam, Ki Hyeong Lee, Kazuhiko Nakagawa, Natasha B. Leighl, Astrid McKeown, Naoyuki Nogami, Thanyanan Reungwetwattana, Johan Vansteenkiste, Eun Kyung Cho, Alessandro Bertolini, Andrew P. Brown, Byoung Chul Cho, Manuel Cobo, Rachel Hodge, Isamu Okamoto, Sabine Bohnet, Yuri Rukazenkov
Publikováno v:
Journal of Clinical Oncology. 36:3290-3297
Purpose We report CNS efficacy of osimertinib versus standard epidermal growth factor receptor ( EGFR) tyrosine kinase inhibitors (TKIs) in patients with untreated EGFR-mutated advanced non–small-cell lung cancer from the phase III FLAURA study. Pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::807615d85d68fa29eaae9d5c423bb178
https://doi.org/10.1200/jco.2018.78.3118
https://doi.org/10.1200/jco.2018.78.3118
Autor:
Nobuyuki Katakami, Rachel Hodge, Masaharu Shinkai, Terufumi Kato, Isamu Okamoto, Toyoaki Hida, Hiroaki Akamatsu, Fumio Imamura, Hirohiko Uchida, Young Hak Kim
Publikováno v:
Cancer Science. 109:1930-1938
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the first-line treatment for patients with EGFR mutant non-small-cell lung cancer (NSCLC). However, most patients become resistant to these drugs, so their disease progress
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b825f3ef9fe488a8d14bfc9de73bd9c7
https://doi.org/10.1111/cas.13623
https://doi.org/10.1111/cas.13623